Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3‐ and 6‐month periodicities

Jean‐Claude Trinchet, Cendrine Chaffaut, Valérie Bourcier, Françoise Degos, Jean Henrion, Hélène Fontaine, Dominique Roulot, Ariane Mallat, Sophie Hillaire, Paul Cales, Isabelle Ollivier, Jean‐Pierre Vinel, Philippe Mathurin, Jean‐Pierre Bronowicki, Valérie Vilgrain, Gisèle N'Kontchou, Michel Beaugrand, Sylvie Chevret, for the Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire (GRETCH) – 2 December 2011 – Detection of small hepatocellular carcinoma (HCC) eligible for curative treatment is increased by surveillance, but its optimal periodicity is still debated.

Connective tissue growth factor autocriny in human hepatocellular carcinoma: Oncogenic role and regulation by epidermal growth factor receptor/yes‐associated protein–mediated activation

Raquel Urtasun, Maria U. Latasa, Maria I. Demartis, Stella Balzani, Saioa Goñi, Oihane Garcia‐Irigoyen, Maria Elizalde, Maria Azcona, Rosa M. Pascale, Francesco Feo, Paulette Bioulac‐Sage, Charles Balabaud, Jordi Muntané, Jesus Prieto, Carmen Berasain, Matias A. Avila – 2 December 2011 – The identification of molecular mechanisms involved in the maintenance of the transformed phenotype of hepatocellular carcinoma (HCC) cells is essential for the elucidation of therapeutic strategies.

Radiofrequency ablation of high‐grade dysplastic nodules

Yun Ku Cho, Jin Wook Chung, Yoonjung Kim, Hyun Je Cho, Soo Hyun Yang – 2 December 2011 – High‐grade dysplastic nodules (HGDNs) are known to be premalignant lesions of hepatocellular carcinoma (HCC). We devised a model to estimate the long‐term survival benefit of treating HGDNs by radiofrequency ablation (RFA) (Group I), as compared with regular follow‐up and timely treatment by resection (Group II). A hypothetical 60‐year‐old compensated patient with cirrhosis was assumed.

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS‐790052 in Humans: In Vitro and In Vivo Correlations

Robert A. Fridell, Chunfu Wang, Jin‐Hua Sun, Donald R. O'Boyle, Peter Nower, Lourdes Valera, Dike Qiu, Susan Roberts, Xin Huang, Bernadette Kienzle, Marc Bifano, Richard E. Nettles, Min Gao – 2 December 2011 – The NS5A replication complex inhibitor, BMS‐790052, inhibits hepatitis C virus (HCV) replication with picomolar potency in preclinical assays. This potency translated in vivo to a substantial antiviral effect in a single‐ascending dose study and a 14‐day multiple‐ascending dose (MAD) monotherapy study.

Protease profiling of liver fibrosis reveals the ADAM metallopeptidase with thrombospondin type 1 motif, 1 as a central activator of transforming growth factor beta

Katia Bourd‐Boittin, Dominique Bonnier, Anthony Leyme, Bernard Mari, Pierre Tuffery, Michel Samson, Frédéric Ezan, Georges Baffet, Nathalie Theret – 2 December 2011

Effects of bilirubin and sera from jaundiced patients on osteoblasts: Contribution to the development of osteoporosis in liver diseases

Silvia Ruiz‐Gaspà, Angels Martinez‐Ferrer, Nuria Guañabens, Marta Dubreuil, Pilar Peris, Anna Enjuanes, Maria Jesús Martinez de Osaba, Luisa Alvarez, Ana Monegal, Andrés Combalia, Albert Parés – 2 December 2011 – Low bone formation is considered to be the main feature in osteoporosis associated with cholestatic and end‐stage liver diseases, although the consequences of retained substances in chronic cholestasis on bone cells have scarcely been studied.

Subscribe to